Inhaled Nitric Oxide and Cerebral Malaria: Basis of a Strategy for Buying Time for Pharmacotherapy

Pediatric Infectious Disease Journal

Volumn 31, Issue 12, 2012, Pages e250-e254

  Bergmark, Brian ^a   Bergmark, Regan ^a   Beaudrap, Pierre De ^a   Boum, Yap ^a   Mwanga Amumpaire, Juliet ^a   Carroll, Ryan ^a   Zapol, Warren ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cerebral malaria; Inhaled nitric oxide; Nitric oxide synthase; Plasmodium falciparum

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR;

BIOAVAILABILITY; BRAIN MALARIA; CYTOKINE RESPONSE; ENZYME ACTIVATION; EXOCYTOSIS; HEMOLYSIS; HUMAN; INTRACELLULAR SIGNALING; INTRACRANIAL HYPERTENSION; MALARIA; NONHUMAN; PATHOPHYSIOLOGY; PLASMODIUM FALCIPARUM; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION; VASODILATATION;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; MALARIA, CEREBRAL; MALARIA, FALCIPARUM; NITRIC OXIDE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; UGANDA;

EID: 84870916708     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318266c113     Document Type: Review

References (59)

1. Clark IA, Alleva LM, Mills AC, et al. Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev. 2004;17:509-39 table of contents
2. World Health Organization. World Malaria Report 2010. 2010 Geneva, Switzerland World Health Organization
3. World Health Organization. WHO Guidelines for the Treatment of Malaria. 2010 Geneva, Switzerland World Health Organization
4. Idro R, Jenkins NE, Newton CR. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 2005;4:827-840
5. Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med. 2004;10:143-145
6. Dondorp AM, Fanello CI, Hendriksen IC, et al.AQUAMAT group. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647-1657
7. John CC, Bangirana P, Byarugaba J, et al. Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics. 2008;122:e92-e99
8. Lin S, Fagan KA, Li KX, et al. Sustained endothelial nitric-oxide synthase activation requires capacitative Ca2+ entry. J Biol Chem. 2000;275:17979-17985
9. Bloch KD, Ichinose F, Roberts JD Jr, et al. Inhaled NO as a therapeutic agent. Cardiovasc Res. 2007;75:339-348
10. Rassaf T, Preik M, Kleinbongard P, et al. Evidence for in vivo transport of bioactive nitric oxide in human plasma. J Clin Invest. 2002;109:1241-1248
11. Tuteja N, Chandra M, Tuteja R, et al. Nitric Oxide as a Unique Bioactive Signaling Messenger in Physiology and Pathophysiology. J Biomed Biotechnol. 2004;2004:227-237
12. Nagasaka Y, Buys ES, Spagnolli E, et al. Soluble guanylate cyclase-a1 is required for the cardioprotective effects of inhaled nitric oxide. Am J Physiol Heart Circ Physiol. 2011;300:H1477-H1483
13. Siriussawakul A, Zaky A, Lang JD. Role of nitric oxide in hepatic ischemia-reperfusion injury. World J Gastroenterol. 2010;16:6079-6086
14. Rassaf T, Kleinbongard P, Preik M, et al. Plasma nitrosothiols contribute to the systemic vasodilator effects of intravenously applied NO: experimental and clinical Study on the fate of NO in human blood. Circ Res. 2002;91:470-477
15. Yeo TW, Lampah DA, Tjitra E, et al. Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis. 2009;200:1522-1529
16. Anstey NM, Weinberg JB, Hassanali MY, et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med. 1996;184:557-567
17. Maciejewski JP, Selleri C, Sato T, et al. Nitric oxide suppression of human hematopoiesis in vitro. Contribution to inhibitory action of interferon-gamma and tumor necrosis factor-alpha. J Clin Invest. 1995;96:1085-1092
18. Newton CR, Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol Ther. 1998;79:1-53
19. Clark IA, Awburn MM, Whitten RO, et al. Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. Malar J. 2003;2:6
20. Stevenson MM, Riley EM. Innate immunity to malaria. Nat Rev Immunol. 2004;4:169-180
21. Kwiatkowski D, Hill AV, Sambou I, et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet. 1990;336:1201-1204
22. McGuire W, Hill AV, Allsopp CE, et al. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature. 1994;371:508-510
23. Brown GC. Regulation of mitochondrial respiration by nitric oxide inhibition of cytochrome c oxidase. Biochim Biophys Acta. 2001;1504:46-57
24. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235-239
25. Matsushita K, Morrell CN, Cambien B, et al. Nitric oxide regulates exocytosis by S-nitrosylation of N-ethylmaleimide-sensitive factor. Cell. 2003;115:139-150
26. Serirom S, Raharjo WH, Chotivanich K, et al. Anti-adhesive effect of nitric oxide on Plasmodium falciparum cytoadherence under flow. Am J Pathol. 2003;162:1651-1660
27. Beare NA, Southern C, Chalira C, et al. Prognostic significance and course of retinopathy in children with severe malaria. Arch Ophthalmol. 2004;122:1141-1147
28. White VA, Lewallen S, Beare NA, et al. Retinal pathology of pediatric cerebral malaria in Malawi. PLoS ONE. 2009;4:e4317
29. Waller D, Crawley J, Nosten F, et al. Intracranial pressure in childhood cerebral malaria. Trans R Soc Trop Med Hyg. 1991;85:362-364
30. Lopansri BK, Anstey NM, Weinberg JB, et al. Low plasma arginine concentrations in children with cerebral malaria and decreased nitric oxide production. Lancet. 2003;361:676-678
31. Yeo TW, Lampah DA, Gitawati R, et al. Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med. 2007;204:2693-2704
32. Yeo TW, Lampah DA, Tjitra E, et al. Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog. 2010;6:e1000868
33. Gramaglia I, Sobolewski P, Meays D, et al. Low nitric oxide bioavailability contributes to the genesis of experimental cerebral malaria. Nat Med. 2006;12:1417-1422
34. Favre N, Ryffel B, Rudin W. The development of murine cerebral malaria does not require nitric oxide production. Parasitology. 1999;118(Pt 2):135-138
35. Cabrales P, Zanini GM, Meays D, et al. Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology. J Infect Dis. 2011;203:1454-1463
36. Serghides L, Kim H, Lu Z, et al. Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malaria. PLoS ONE. 2011;6:e27714
37. Al Yaman FM, Mokela D, Genton B, et al. Association between serum levels of reactive nitrogen intermediates and coma in children with cerebral malaria in Papua New Guinea. Trans R Soc Trop Med Hyg. 1996;90:270-273
38. Weiss G, Thuma PE, Biemba G, et al. Cerebrospinal fluid levels of biopterin, nitric oxide metabolites, and immune activation markers and the clinical course of human cerebral malaria. J Infect Dis. 1998;177:1064-1068
39. Agina AA, Abd-Allah SH. Plasma levels of nitric oxide in association with severe Plasmodium falciparum in Yemen. J Egypt Soc Parasitol. 1999;29:215-222
40. Cot S, Ringwald P, Mulder B, et al. Nitric oxide in cerebral malaria. J Infect Dis. 1994;169:1417-1418
41. Perkins DJ, Kremsner PG, Schmid D, et al. Blood mononuclear cell nitric oxide production and plasma cytokine levels in healthy gabonese children with prior mild or severe malaria. Infect Immun. 1999;67:4977-4981
42. Boutlis CS, Hobbs MR, Marsh RL, et al. Inducible nitric oxide synthase (NOS2) promoter CCTTT repeat polymorphism: relationship to in vivo nitric oxide production/NOS activity in an asymptomatic malaria-endemic population. Am J Trop Med Hyg. 2003;69:569-573
43. Kun JF, Mordmüller B, Perkins DJ, et al. Nitric oxide synthase 2(Lambaréné) (G-954C), increased nitric oxide production, and protection against malaria. J Infect Dis. 2001;184:330-336
44. Levesque MC, Hobbs MR, Anstey NM, et al. Nitric oxide synthase type 2 promoter polymorphisms, nitric oxide production, and disease severity in Tanzanian children with malaria. J Infect Dis. 1999;180:1994-2002
45. Planche T, Macallan DC, Sobande T, et al. Nitric oxide generation in children with malaria and the NOS2G-954C promoter polymorphism. Am J Physiol Regul Integr Comp Physiol. 2010;299:R1248-R1253
46. Parikh S, Dorsey G, Rosenthal PJ. Host polymorphisms and the incidence of malaria in Ugandan children. Am J Trop Med Hyg. 2004;71:750-753
47. Cramer JP, Nüssler AK, Ehrhardt S, et al. Age-dependent effect of plasma nitric oxide on parasite density in Ghanaian children with severe malaria. Trop Med Int Health. 2005;10:672-680
48. Burgner D, Usen S, Rockett K, et al. Nucleotide and haplotypic diversity of the NOS2A promoter region and its relationship to cerebral malaria. Hum Genet. 2003;112:379-386
49. Mombo LE, Ntoumi F, Bisseye C, et al. Human genetic polymorphisms and asymptomatic Plasmodium falciparum malaria in Gabonese schoolchildren. Am J Trop Med Hyg. 2003;68:186-190
50. Hobbs MR, Udhayakumar V, Levesque MC, et al. A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet. 2002;360:1468-1475
51. Ohashi J, Naka I, Patarapotikul J, et al. Significant association of longer forms of CCTTT Microsatellite repeat in the inducible nitric oxide synthase promoter with severe malaria in Thailand. J Infect Dis. 2002;186:578-581
52. Cramer JP, Mockenhaupt FP, Ehrhardt S, et al. iNOS promoter variants and severe malaria in Ghanaian children. Trop Med Int Health. 2004;9:1074-1080
53. Komatsu T, Bi Z, Reiss CS. Interferon-gamma induced type I nitric oxide synthase activity inhibits viral replication in neurons. J Neuroimmunol. 1996;68:101-108
54. Saur D, Vanderwinden JM, Seidler B, et al. Single-nucleotide promoter polymorphism alters transcription of neuronal nitric oxide synthase exon 1c in infantile hypertrophic pyloric stenosis. Proc Natl Acad Sci USA. 2004;101:1662-1667
55. Dhangadamajhi G, Mohapatra BN, Kar SK, et al. Genetic variation in neuronal nitric oxide synthase (nNOS) gene and susceptibility to cerebral malaria in Indian adults. Infect Genet Evol. 2009;9:908-911
56. Dhangadamajhi G, Mohapatra BN, Kar SK, et al. Endothelial nitric oxide synthase gene polymorphisms and Plasmodium falciparum infection in Indian adults. Infect Immun. 2009;77:2943-2947
57. Dhangadamajhi G, Mohapatra BN, Kar SK, et al. A new allele (eNOS4e) in the intron 4 (VNTR) of eNOS gene in malaria infected individuals of the population of Orissa (an eastern Indian state). Nitric Oxide. 2010;22:58-59
58. Hu H, Liang H, Li J, et al. Study on production of inhaled nitric oxide for medical applications by pulsed discharge. IEEE Trans Plas Sci. 2007;35:619
59. Carpenter AW, Schoenfisch MH. Nitric oxide release: part II. Therapeutic applications. Chem Soc Rev. 2012;41:3742-3752